🔗 GLP-1 API Supply Chain Deep Analysis
Report ID: MKI-GLP1SC-2026-001 | Release Date: July 2026
Coverage: GLP-1 API supply chain, CDMO capacity, price trends, bottleneck analysis
1. Supply Chain Panorama
The GLP-1 API (Active Pharmaceutical Ingredient) supply chain represents the biggest structural bottleneck in the global peptide market. The synthesis routes for semaglutide and tirzepatide are extremely complex, with single-batch production cycles lasting weeks to months, resulting in a persistently tight global API supply situation.
Core Contradiction
GLP-1 drug demand growth (increasing 40%+ annually) far outpaces API capacity expansion (increasing 25-30% annually), with the supply-demand gap continuing to widen through 2024-2026.
2. API Synthesis Technology and Raw Materials
2.1 Synthesis Route Comparison
| Molecule |
Synthesis Method |
Amino Acid Length |
Synthesis Steps |
Overall Yield |
Single Batch Cycle |
| Semaglutide |
SPPS + Liquid-phase modification |
31 |
45-50 steps |
1-3% |
3-4 weeks |
| Tirzepatide |
SPPS |
39 |
60+ steps |
<2% |
3-4 months |
| Liraglutide |
SPPS |
31 (fatty acid side chain) |
35 steps |
3-5% |
2-3 weeks |
| Dulaglutide |
Fermentation + Fc fusion |
— (Fc fusion protein) |
— |
Higher |
Faster |
| Raw Material/Intermediate |
Supply Situation |
Price Trend |
Domestic Substitution |
| Fmoc-amino acid derivatives |
Ample |
Stable |
✅ Domesticated |
| Protected amino acids |
Ample |
Stable |
✅ Domesticated |
| Resin carriers (Wang resin, etc.) |
Ample |
Stable |
✅ Domestic substitution complete |
| Long-chain fatty acids (C18/C20) |
Tight |
Rising |
⚠️ Partially import-dependent |
| Coupling reagents (HATU/HBTU, etc.) |
Ample |
Stable |
✅ Domesticated |
| High-purity cleavage reagents (TFA) |
Ample |
Minor fluctuations |
✅ Domestic supply ample |
| Purification resin/media |
Tight |
Rising |
⚠️ High import dependency |
3. Global GLP-1 API Manufacturers
3.1 Key Suppliers — Capacity and Customers
| Company |
Country |
2024 Capacity (kg/yr) |
2026E Capacity (kg/yr) |
Core Customers |
| Novo Nordisk (in-house) |
Denmark |
15,000 |
30,000 |
Self-supply |
| Eli Lilly (in-house) |
USA |
8,000 |
20,000 |
Self-supply |
| WuXi AppTec (WuXi TIDES) |
China |
3,500 |
8,000 |
Multiple international pharma |
| Sinopeptide |
China |
2,000 |
4,000 |
Overseas generic pharma |
| Bachem |
Switzerland |
1,500 |
2,500 |
Multiple innovative pharma |
| Jiuzhou Pharma |
China |
500 |
1,500 |
Domestic pharma |
| Shengnuo Biotechnology |
China |
400 |
1,000 |
Domestic pharma |
| Total |
— |
~30,900 |
~67,000 |
— |
3.2 China's Role in the GLP-1 API Supply Chain
China plays an increasingly critical role in the global GLP-1 API supply chain:
| Role |
China Share (2024) |
2030E Share |
Description |
| GLP-1 innovator API contract manufacturing |
~20% |
~35% |
WuXi AppTec as main contract manufacturer for Novo/Lilly |
| GLP-1 generic API supply |
~70% |
~80% |
Sinopeptide, Jiuzhou supplying Indian/Chinese generic pharma |
| GLP-1 intermediates/fragments |
~85% |
~90% |
China monopolizes key intermediate supply |
| Synthesis resins/reagents |
~75% |
~80% |
China is world's largest resin/reagent supplier |
4. CDMO Capacity and Technical Capabilities
4.1 Core CDMO Technical Capability Comparison
| Company |
Synthesis Technology |
Purification |
Continuous Flow Capability |
Lyophilization Capacity |
GMP Grade |
| WuXi AppTec |
SPPS+LPPS |
Prep HPLC |
✅ Yes |
Large-scale |
nGMP+cGMP |
| Sinopeptide |
SPPS |
Prep HPLC |
⚠️ Under construction |
Medium-scale |
cGMP |
| Asymchem |
SPPS+Continuous Flow |
Prep HPLC |
✅ Leading |
Medium-scale |
nGMP+cGMP |
| Shengnuo Biotechnology |
SPPS |
Prep HPLC |
❌ No |
Medium-scale |
cGMP |
| Bachem |
SPPS+LPPS |
Prep HPLC |
✅ Yes |
Large-scale |
cGMP |
| Lonza |
LPPS |
— |
✅ Yes |
Large-scale |
cGMP |
4.2 Capacity Utilization
| Company |
2024 Capacity Utilization |
2025E Utilization |
Order Backlog |
| WuXi AppTec |
95%+ |
95%+ |
~$2B |
| Sinopeptide |
95%+ |
100% |
Contracts saturated |
| Asymchem |
80% |
85% |
Growing |
| Bachem |
90% |
90% |
Stable |
| Jiuzhou Pharma |
70% |
80% |
Rapid ramp-up |
5. Cost and Pricing Analysis
5.1 API Price Trends
| Year |
Semaglutide API ($/g) |
Tirzepatide API ($/g) |
Liraglutide API ($/g) |
| 2022 |
$180-220 |
— |
$80-120 |
| 2023 |
$200-280 |
$250-350 |
$100-150 |
| 2024 |
$250-320 |
$300-400 |
$120-160 |
| 2025E |
$220-280 |
$280-350 |
$100-130 |
| 2026E (generics entering) |
$150-220 |
$200-280 |
$70-100 |
| 2028E (generic volume) |
$80-120 |
$100-150 |
$40-60 |
5.2 Cost Structure Analysis
| Cost Item |
Share of API Cost |
Trend |
| Amino acid raw materials |
25-30% |
Stable, fully domesticated |
| Synthesis reagents and resins |
15-20% |
Slightly rising |
| Purification and separation |
20-25% |
Diluted at scale |
| QC/QA testing |
10-15% |
Compliance costs rising |
| Labor and engineering |
10-15% |
Rising (5-8%/yr) |
| Environmental and wastewater |
5-10% |
Tightening (10%+/yr) |
6. Bottleneck Analysis
6.1 Current Major Bottlenecks
| Bottleneck |
Severity |
Root Cause |
Possible Solutions |
| SPPS low efficiency |
★★★★★ |
35-60 step reactions, yield only 1-3% |
LPPS/Continuous flow + fragment condensation |
| Purification yield loss |
★★★★☆ |
HPLC purification output only 70-80% |
High-performance media + process optimization |
| EPA/DPA impurity control |
★★★★☆ |
GLP-1 APIs prone to difficult-to-remove impurities |
Process optimization + supercritical chromatography |
| Long capacity expansion cycle |
★★★★☆ |
New capacity takes 2-3 years |
CDMO outsourcing + technology licensing |
| Insufficient lyophilization capacity |
★★★☆☆ |
Injectable lyophilization bottleneck |
Introducing large-scale lyophilizers |
6.2 Technology Breakthrough Directions
- Continuous Flow SPPS: Can reduce synthesis time from weeks to days, improving yield 2-3x
- Fragment Condensation Strategy: Split long-chain peptides into multiple short fragments synthesized separately then condensed, improving overall yield
- Enzymatic Synthesis: Utilizing enzyme catalysis to synthesize specific peptide bonds, reducing side reactions and impurities
- AI-Assisted Process Optimization: Using machine learning to optimize reaction conditions, shortening process development cycles
- Alternative Resin Technology: Next-generation high-loading resins increasing output per batch
7. Future Outlook
7.1 Supply Landscape Forecast
| Year |
Global Effective Capacity (kg/yr) |
Demand (kg/yr) |
Supply-Demand Status |
| 2025E |
16,000 |
20,000 |
25% gap |
| 2026E |
25,000 |
28,000 |
11% gap |
| 2027E |
35,000 |
36,000 |
3% slight gap |
| 2028E |
45,000 |
45,000 |
Balanced |
| 2030E |
65,000 |
60,000 |
Slight oversupply |
7.2 Key Trend Assessments
- 2024-2026: API remains tight, prices stay elevated, supplier bargaining power strong
- 2026-2027: Generic API begins large-scale volume release, price inflection point emerges
- 2027-2028: Supply-demand approaches balance, API prices decline 30-40%
- Post-2028: Oral GLP-1 drugs further increase, API demand structure changes
Conclusion
The GLP-1 API supply chain is the most critical competitive element in the peptide industry today. Chinese CDMO companies, leveraging capacity expansion speed and cost advantages, are rapidly increasing their global market share. For both innovative and generic drug companies, securing stable, high-quality API/CDMO suppliers is a key prerequisite for participating in the GLP-1 market.
Supply Chain Data Sources
Supply-demand data compiled from publicly available information from WuXi AppTec, Sinopeptide, Bachem and other companies, as well as industry interviews. API price data based on bulk procurement quotation ranges.
SENO Biotechnology — GLP-1 API Professional Supplier. SENO Biotechnology provides semaglutide, tirzepatide, and other GLP-1 APIs as well as peptide CDMO custom services, strictly following cGMP standards to support customer supply chain stability. For details please visit SENO GLP-1 CDMO Services.